Rational Therapy of Clostridium difficile Infections.

Viszeralmedizin Pub Date : 2014-10-01 DOI:10.1159/000366302
Peter M Keller, Marko H Weber
{"title":"Rational Therapy of Clostridium difficile Infections.","authors":"Peter M Keller,&nbsp;Marko H Weber","doi":"10.1159/000366302","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Clostridium difficile infections (CDI) are increasingly important in patients with antibiotic treatments, ranging from mild, self-limiting to severe, life-threatening disease. Currently, diagnostic algorithms and treatment guidelines are being adapted to novel tests and therapeutic options for recurrent CDI.</p><p><strong>Methods: </strong>A systematic literature search using the terms 'Clostridium difficile' and 'treatment' was carried out. Current guidelines are being discussed from a clinical point of view.</p><p><strong>Results: </strong>State-of-the-art diagnostics for C. difficile diagnosis rely on the patient's history, clinical symptoms, and laboratory examination of stool. Recommendations are in favour of glutamate dehydrogenase (GDH) screening tests and confirmatory detection of C. difficile toxin genes (polymerase chain reaction (PCR)). Therapeutic strategies depend on disease severity (mild vs. severe) and endorse metronidazole and vancomycin as well as fidaxomycin for recurrent disease. In very severe cases, surgical therapy is recommended. For relapsing diseases, faecal transfer is considered as a therapeutic option if available.</p><p><strong>Conclusion: </strong>Current guidelines have been adapted to new pathways in diagnosing CDI and have included statements on novel therapeutic options such as fidaxomycin and faecal transplant for recurrent disease. Depending on the severity of the disease, standard therapy with either metronidazole or vancomycin is recommended.</p>","PeriodicalId":49114,"journal":{"name":"Viszeralmedizin","volume":"30 5","pages":"304-9"},"PeriodicalIF":0.0000,"publicationDate":"2014-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000366302","citationCount":"10","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Viszeralmedizin","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1159/000366302","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 10

Abstract

Background: Clostridium difficile infections (CDI) are increasingly important in patients with antibiotic treatments, ranging from mild, self-limiting to severe, life-threatening disease. Currently, diagnostic algorithms and treatment guidelines are being adapted to novel tests and therapeutic options for recurrent CDI.

Methods: A systematic literature search using the terms 'Clostridium difficile' and 'treatment' was carried out. Current guidelines are being discussed from a clinical point of view.

Results: State-of-the-art diagnostics for C. difficile diagnosis rely on the patient's history, clinical symptoms, and laboratory examination of stool. Recommendations are in favour of glutamate dehydrogenase (GDH) screening tests and confirmatory detection of C. difficile toxin genes (polymerase chain reaction (PCR)). Therapeutic strategies depend on disease severity (mild vs. severe) and endorse metronidazole and vancomycin as well as fidaxomycin for recurrent disease. In very severe cases, surgical therapy is recommended. For relapsing diseases, faecal transfer is considered as a therapeutic option if available.

Conclusion: Current guidelines have been adapted to new pathways in diagnosing CDI and have included statements on novel therapeutic options such as fidaxomycin and faecal transplant for recurrent disease. Depending on the severity of the disease, standard therapy with either metronidazole or vancomycin is recommended.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
艰难梭菌感染的合理治疗。
背景:艰难梭菌感染(CDI)在接受抗生素治疗的患者中越来越重要,从轻度、自限性到严重、危及生命的疾病。目前,诊断算法和治疗指南正在适应复发性CDI的新测试和治疗方案。方法:使用“艰难梭菌”和“治疗”进行系统的文献检索。目前的指导方针正在从临床的角度进行讨论。结果:目前最先进的艰难梭菌诊断依赖于患者的病史、临床症状和粪便实验室检查。建议支持谷氨酸脱氢酶(GDH)筛选试验和艰难梭菌毒素基因的确证检测(聚合酶链反应(PCR))。治疗策略取决于疾病的严重程度(轻度和严重),并支持甲硝唑和万古霉素以及非达霉素治疗复发性疾病。在非常严重的情况下,建议手术治疗。对于复发性疾病,如果可行,粪便转移被认为是一种治疗选择。结论:目前的指南已经适应了诊断CDI的新途径,并包括了新的治疗选择,如非达霉素和粪便移植治疗复发性疾病的声明。根据疾病的严重程度,推荐使用甲硝唑或万古霉素进行标准治疗。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Viszeralmedizin
Viszeralmedizin GASTROENTEROLOGY & HEPATOLOGY-SURGERY
自引率
0.00%
发文量
0
审稿时长
>12 weeks
期刊最新文献
How Effective Are Percutaneous Liver-Directed Therapies in Patients with Non-Colorectal Liver Metastases? Arterial Therapies of Non-Colorectal Liver Metastases. Current Medical Treatment of Patients with Non-Colorectal Liver Metastases: Primary Tumor Breast Cancer. Ectopic Spleen Tissue – an Underestimated Differential Diagnosis of a Hypervascularised Liver Tumour Precision Medicine and Non-Colorectal Cancer Liver Metastases: Fiction or Reality?
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1